Clin Osteol 2020; 25(1): 45-49

Early non-responders in teriparatide therapy: retrospective analysisReview articles

Masaryk Pavol; Letkovská Alexandra
Národný ústav reumatických chorôb, Piešťany

Teriparatide (TPTD) is a potent osteoanabolic drug. A potential drawback associated with teriparatide treatment is a failure of effect. The incidence of non-responders depends on the definition of lack of response to treatment, baseline bone density, duration of treatment, prior antiresorptive therapy, and measurement accuracy. In our study, we analyzed "early non-responders" after 6 and 12 months of treatment in a group of 306 patients. We identified 36 (11.7 %) patients as early non-responders, of whom 18 after 6 months of treatment and 18 after one year of treatment. There were only 4 men and up to 32 women in the sample, but the percentage of non-responders among the sexes was approximately the same (men: 10.5 %, women: 11.9 %). Early non-responders in glucocorticoid osteoporosis were significantly more represented. Previous antiresorptive therapy, especially bisphosphonates, increased the risk of a lack of response to teriparatide therapy.

Keywords: teriparatide; non-responders

Received: March 19, 2020; Accepted: June 1, 2020; Published: June 11, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Masaryk P, Letkovská A. Early non-responders in teriparatide therapy: retrospective analysis. Clinical Osteology. 2020;25(1):45-49.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Eriksen EF, Keaveny TM, Gallagher ER et al. Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 2014; 67 : 246-256. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2014.07.014>. Go to original source...
    2. Dempster DW, Cosman F, Parisien M et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14(6): 690-709. Dostupné z DOI: <http://dx.doi.org/10.1210/edrv-14-6-690>. Go to original source...
    3. Body JJ, Gaich GA, Scheele WH et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2000; 87(10): 4528-4535. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2002-020334>. Go to original source...
    4. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434-1441. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200105103441904>. Go to original source...
    5. Gallagher JC, Rosen CJ, Chen P et al. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 2006; 39(6): 1268-1275. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2006.06.007>. Go to original source...
    6. Heaney RP, Watson P. Variability in the measured response of bone to teriparatide. Osteoporos Int 2011; 22(6): 1703-1708. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-010-1376-1>. Go to original source...
    7. Elraiyah T, Ahmed AH, Wang Z et al. Predictors of teriparatide treatment failure in patients with low bone mass. Bone Reports 2016; 4 : 17-22. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bonr.2015.11.001>. Go to original source...
    8. Payer J, Tomková S, Jackuliak P et al. Teriparatid v liečbe ťažkej osteoporózy u starších pacientok: výsledky multicentrickej prospektívnej štúdie. Clin Osteol 2018; 23(3): 88-93.
    9. Payer J, Tomková S, Killinger Z et al. 18-mesačná liečba teriparatidom zlepšuje u pacientov s glukokortikoidmi indukovanou osteoporózou hodnoty hustoty kostného minerálu a trabekulárne kostné skóre: výsledky prospektívneho sledovania (register OSTEO.sk). Clin Osteol 2018; 23(4): 138-145.
    10. Minne H, Audran M, Maria E et al. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin 2008; 24(11): 3117-3128. Dostupné z DOI: <http://dx.doi.org/10.1185/03007990802466595>. Go to original source...
    11. Niimi R, Kono T, Nishihara TA et al. A retrospective analysis of nonresponse to daily teriparatide treatment. Osteoporos Int 2016; 27(9): 2845-2853. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-016-3581-z>. Erratum in Erratum to: A retrospective analysis of nonresponse to daily teriparatide treatment. Go to original source...
    12. Niimi R, Kono T, Nishihara A et al. Osteoporos Int 2016; 27(9): 2887-2888. Dostupné z DOI: <http://dx.doi.oerg/10.1007/s00198-016-3625-4>.
    13. Kim SY, Zhang M, Bockman R. Bone Mineral Density Response from Teriparatide in Patients with Osteoporosis. HSSJ 2017; 13(2): 171-177. Dostupné z DOI: <http://dx.doi.org/10.1007/s11420-016-9537-1>. Go to original source...
    14. Cohen A, Stein EM, Recker RR et al. Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Pilot Study. J Clin Endocrinol Metab 2013; 98(5): 1971-1981. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013-1172>. Go to original source...
    15. Ettinger B, San Martin J, Crans G et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19(5): 745-751. Dostupné z DOI: <http://dx.doi.org/10.1359/JBMR.040117>. Go to original source...
    16. Lindsay R, Zhou H, Cosman F et al. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007; 22(4): 495-502. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.070104>. Go to original source...
    17. Borggrefe J, Graeff C, Nickelsen T N el al. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 2010; 25(3): 472-481. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.090820>. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.